Hawkins Richard J 4
4 · PLUS THERAPEUTICS, INC. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Plus Therapeutics (PSTV) Director Richard J. Hawkins Receives RSU Award
What Happened
Richard J. Hawkins, a director of Plus Therapeutics (PSTV), received two restricted stock unit (RSU) awards on May 14, 2026 totaling 7,372 RSUs (3,686 + 3,686). The awards are recorded at $0.00 per unit (no cash exchanged) and are derivative awards that convert to common shares as they vest.
Key Details
- Transaction date: 2026-05-14; Form 4 filed 2026-05-18 (filed four days after the transaction). Form 4s are typically due within 2 business days, so this filing appears later than usual.
- Award type: RSUs (derivative), 3,686 RSUs reported twice = 7,372 RSUs total. Price: $0.00 per RSU; total immediate value reported: $0.
- Vesting (Footnote F1): Each RSU represents a contingent right to one share. Vesting is ratable over four quarters, with 1/4 vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
- Additional footnote (F2): The filing also includes language about option vesting (monthly over 12 months and full vesting at the 2027 Annual Meeting); this pertains to other award terms disclosed in the filing.
- Shares owned after transaction: Not specified in the reported data.
Context
RSU grants are compensation awards that convert into shares as they vest; they are not open-market purchases or sales. Such awards are routine director compensation and do not, by themselves, indicate insider buying or selling sentiment.
Insider Transaction Report
Form 4
Hawkins Richard J
Director
Transactions
- Award
Restricted Stock Units
[F1]2026-05-14+3,686→ 3,686 totalExercise: $0.00→ Common Stock (3,686 underlying) - Award
Stock Option (Right to Buy)
[F2]2026-05-14+3,686→ 3,686 totalExercise: $5.76Exp: 2036-05-14→ Common Stock (3,686 underlying)
Footnotes (2)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
- [F2]The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.
Signature
Andrew Sims, as attorney-in-fact|2026-05-18